- Net sales grew 4% (cc[1], +10% USD) mainly driven by:
- Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide
- Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded access
- Oncology returned to growth (+6% cc) driven by Promacta/Revolade, Tafinlar + Mekinist, Jakavi and recent launches
- Core[1] operating income grew 4% (cc, +11% USD) as higher sales helped support growth and launch investments; Core EPS of USD 1.28, …
- Net sales grew 4% (cc[1], +10% USD) mainly driven by:
- Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide
- Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and expanded access
- Oncology returned to growth (+6% cc) driven by Promacta/Revolade, Tafinlar + Mekinist, Jakavi and recent launches
- Core[1] operating income grew 4% (cc, +11% USD) as higher sales helped support growth and launch investments; Core EPS of USD 1.28, …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia